Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial

BACKGROUND: The delivery of antipseudomonal antibiotics by inhalation to Pseudomonas aeruginosa-infected subjects with non-cystic fibrosis (CF) bronchiectasis is a logical extension of treatment strategies successfully developed in CF bronchiectasis. Dual release ciprofloxacin for inhalation (DRCFI)...

Descripción completa

Detalles Bibliográficos
Autores principales: Serisier, David J, Bilton, Diana, De Soyza, Anthony, Thompson, Philip J, Kolbe, John, Greville, Hugh W, Cipolla, David, Bruinenberg, Paul, Gonda, Igor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Bronchiectasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770250/
https://www.ncbi.nlm.nih.gov/pubmed/23681906
http://dx.doi.org/10.1136/thoraxjnl-2013-203207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770250/
https://www.ncbi.nlm.nih.gov/pubmed/23681906
http://dx.doi.org/10.1136/thoraxjnl-2013-203207

Ejemplares similares